Cargando…

A Journey with LGMD: From Protein Abnormalities to Patient Impact

The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes...

Descripción completa

Detalles Bibliográficos
Autores principales: Georganopoulou, Dimitra G., Moisiadis, Vasilis G., Malik, Firhan A., Mohajer, Ali, Dashevsky, Tanya M., Wuu, Shirley T., Hu, Chih-Kao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190568/
https://www.ncbi.nlm.nih.gov/pubmed/34110586
http://dx.doi.org/10.1007/s10930-021-10006-9
_version_ 1783705711756181504
author Georganopoulou, Dimitra G.
Moisiadis, Vasilis G.
Malik, Firhan A.
Mohajer, Ali
Dashevsky, Tanya M.
Wuu, Shirley T.
Hu, Chih-Kao
author_facet Georganopoulou, Dimitra G.
Moisiadis, Vasilis G.
Malik, Firhan A.
Mohajer, Ali
Dashevsky, Tanya M.
Wuu, Shirley T.
Hu, Chih-Kao
author_sort Georganopoulou, Dimitra G.
collection PubMed
description The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes in the family of LGMDs further adds to the heterogeneity of the disease. Meanwhile, better understanding of the phenotype led to the reconsideration of the disease definition, which resulted in eight old subtypes to be no longer recognized officially as LGMD and five new diseases to be added to the LGMD family. The unique variabilities of LGMD stem from genetic mutations, which then lead to protein and ultimately muscle dysfunction. Herein, we review the LGMD pathway, starting with the genetic mutations that encode proteins involved in muscle maintenance and repair, and including the genotype–phenotype relationship of the disease, the epidemiology, disease progression, burden of illness, and emerging treatments.
format Online
Article
Text
id pubmed-8190568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81905682021-06-10 A Journey with LGMD: From Protein Abnormalities to Patient Impact Georganopoulou, Dimitra G. Moisiadis, Vasilis G. Malik, Firhan A. Mohajer, Ali Dashevsky, Tanya M. Wuu, Shirley T. Hu, Chih-Kao Protein J Article The limb-girdle muscular dystrophies (LGMD) are a collection of genetic diseases united in their phenotypical expression of pelvic and shoulder area weakness and wasting. More than 30 subtypes have been identified, five dominant and 26 recessive. The increase in the characterization of new genotypes in the family of LGMDs further adds to the heterogeneity of the disease. Meanwhile, better understanding of the phenotype led to the reconsideration of the disease definition, which resulted in eight old subtypes to be no longer recognized officially as LGMD and five new diseases to be added to the LGMD family. The unique variabilities of LGMD stem from genetic mutations, which then lead to protein and ultimately muscle dysfunction. Herein, we review the LGMD pathway, starting with the genetic mutations that encode proteins involved in muscle maintenance and repair, and including the genotype–phenotype relationship of the disease, the epidemiology, disease progression, burden of illness, and emerging treatments. Springer US 2021-06-10 2021 /pmc/articles/PMC8190568/ /pubmed/34110586 http://dx.doi.org/10.1007/s10930-021-10006-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Georganopoulou, Dimitra G.
Moisiadis, Vasilis G.
Malik, Firhan A.
Mohajer, Ali
Dashevsky, Tanya M.
Wuu, Shirley T.
Hu, Chih-Kao
A Journey with LGMD: From Protein Abnormalities to Patient Impact
title A Journey with LGMD: From Protein Abnormalities to Patient Impact
title_full A Journey with LGMD: From Protein Abnormalities to Patient Impact
title_fullStr A Journey with LGMD: From Protein Abnormalities to Patient Impact
title_full_unstemmed A Journey with LGMD: From Protein Abnormalities to Patient Impact
title_short A Journey with LGMD: From Protein Abnormalities to Patient Impact
title_sort journey with lgmd: from protein abnormalities to patient impact
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190568/
https://www.ncbi.nlm.nih.gov/pubmed/34110586
http://dx.doi.org/10.1007/s10930-021-10006-9
work_keys_str_mv AT georganopouloudimitrag ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT moisiadisvasilisg ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT malikfirhana ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT mohajerali ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT dashevskytanyam ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT wuushirleyt ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT huchihkao ajourneywithlgmdfromproteinabnormalitiestopatientimpact
AT georganopouloudimitrag journeywithlgmdfromproteinabnormalitiestopatientimpact
AT moisiadisvasilisg journeywithlgmdfromproteinabnormalitiestopatientimpact
AT malikfirhana journeywithlgmdfromproteinabnormalitiestopatientimpact
AT mohajerali journeywithlgmdfromproteinabnormalitiestopatientimpact
AT dashevskytanyam journeywithlgmdfromproteinabnormalitiestopatientimpact
AT wuushirleyt journeywithlgmdfromproteinabnormalitiestopatientimpact
AT huchihkao journeywithlgmdfromproteinabnormalitiestopatientimpact